{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:50:22Z","timestamp":1784868622622,"version":"3.55.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72174110"],"award-info":[{"award-number":["72174110"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40273-025-01549-1","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T12:34:34Z","timestamp":1762173274000},"page":"187-205","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mapping Health State Utility from Disease-Specific Measures in Spinal Muscular Atrophy and Paroxysmal Nocturnal Hemoglobinuria"],"prefix":"10.1007","volume":"44","author":[{"given":"Ziwen","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaofan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8144-6220","authenticated-orcid":false,"given":"Shunping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"issue":"1","key":"1549_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0936-x","volume":"13","author":"P Kaufmann","year":"2018","unstructured":"Kaufmann P, Pariser AR, Austin C. From scientific discovery to treatments for rare diseases: the view from the National Center for Advancing Translational Sciences\u2014Office of Rare Diseases Research. Orphanet J Rare Dis. 2018;13(1):196. https:\/\/doi.org\/10.1186\/s13023-018-0936-x.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"1549_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","volume":"28","author":"S Nguengang Wakap","year":"2020","unstructured":"Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28(2):165\u201373. https:\/\/doi.org\/10.1038\/s41431-019-0508-0.","journal-title":"Eur J Hum Genet"},{"issue":"12","key":"1549_CR3","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.jval.2020.06.020","volume":"23","author":"AYL Chan","year":"2020","unstructured":"Chan AYL, Chan VKY, Olsson S, Fan M, Jit M, Gong M, et al. Access and unmet needs of orphan drugs in 194 countries and 6 areas: a global policy review with content analysis. Value Health. 2020;23(12):1580\u201391. https:\/\/doi.org\/10.1016\/j.jval.2020.06.020.","journal-title":"Value Health"},{"key":"1549_CR4","unstructured":"EvaluatePharma. Orphan drug report 2013. 2013. https:\/\/www.myobase.org\/doc_num.php?explnum_id=9824. Accessed 7 Oct 2025."},{"issue":"4","key":"1549_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152866","volume":"11","author":"A Asante","year":"2016","unstructured":"Asante A, Price J, Hayen A, Jan S, Wiseman V. Equity in health care financing in low- and middle-income countries: a systematic review of evidence from studies using benefit and financing incidence analyses. PLoS ONE. 2016;11(4):e0152866. https:\/\/doi.org\/10.1371\/journal.pone.0152866.","journal-title":"PLoS ONE"},{"issue":"1","key":"1549_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12939-024-02225-0","volume":"23","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zhou N, Li B, Lv Z, Duan S, Li X, et al. Utilization and affordability of health insurance coverage for rare disease drugs in a first-tier city in Northeast China from 2018 to 2021: a study based on the health insurance claims database. Int J Equity Health. 2024;23(1):151. https:\/\/doi.org\/10.1186\/s12939-024-02225-0.","journal-title":"Int J Equity Health"},{"key":"1549_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2019.00416","volume":"7","author":"M Czech","year":"2019","unstructured":"Czech M, Baran-Kooiker A, Atikeler K, Demirtshyan M, Gaitova K, Holownia-Voloskova M, et al. A review of rare disease policies and orphan drug reimbursement systems in 12 Eurasian countries. Front Public Health. 2019;7:416. https:\/\/doi.org\/10.3389\/fpubh.2019.00416.","journal-title":"Front Public Health"},{"key":"1549_CR8","volume-title":"NICE process and methods guides. Guide to the methods of Technology Appraisal 2013","author":"National Institute for Health and Care Excellence","year":"2013","unstructured":"National Institute for Health and Care Excellence. NICE process and methods guides. Guide to the methods of Technology Appraisal 2013. London: National Institute for Health and Care Excellence (NICE); 2013."},{"key":"1549_CR9","unstructured":"Chinese Pharmaceutical Association. China guidelines for pharmacoeconomic evaluations (2020). 2020. https:\/\/www.cpa.org.cn\/cpadmn\/attached\/file\/20201203\/1606977380634185.pdf. Accessed 7 Oct 2025."},{"issue":"4","key":"1549_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1524-4733.2006.00116.x","volume":"9","author":"CA Brauer","year":"2006","unstructured":"Brauer CA, Rosen AB, Greenberg D, Neumann PJ. Trends in the measurement of health utilities in published cost-utility analyses. Value Health. 2006;9(4):213\u20138. https:\/\/doi.org\/10.1111\/j.1524-4733.2006.00116.x.","journal-title":"Value Health"},{"issue":"2","key":"1549_CR11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40273-019-00854-w","volume":"38","author":"X Qian","year":"2020","unstructured":"Qian X, Tan RL, Chuang LH, Luo N. Measurement properties of commonly used generic preference-based measures in East and South-East Asia: a systematic review. Pharmacoeconomics. 2020;38(2):159\u201370. https:\/\/doi.org\/10.1007\/s40273-019-00854-w.","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"1549_CR12","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.jval.2025.02.018","volume":"28","author":"B Ruban-Fell","year":"2025","unstructured":"Ruban-Fell B, Wright SD, Abdullah A, Smith A, Upadhyaya S, van Pelt R, et al. Utility studies in rare diseases: a systematic literature review. Value Health. 2025;28(9):1444\u201353. https:\/\/doi.org\/10.1016\/j.jval.2025.02.018.","journal-title":"Value Health"},{"issue":"2","key":"1549_CR13","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jval.2013.12.002","volume":"17","author":"PM Fayers","year":"2014","unstructured":"Fayers PM, Hays RD. Should linking replace regression when mapping from profile-based measures to preference-based measures? Value Health. 2014;17(2):261\u20135. https:\/\/doi.org\/10.1016\/j.jval.2013.12.002.","journal-title":"Value Health"},{"issue":"4","key":"1549_CR14","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00296-019-04273-0","volume":"39","author":"F Fatoye","year":"2019","unstructured":"Fatoye F, Gebrye T, Odeyemi I. Real-world incidence and prevalence of low back pain using routinely collected data. Rheumatol Int. 2019;39(4):619\u201326. https:\/\/doi.org\/10.1007\/s00296-019-04273-0.","journal-title":"Rheumatol Int"},{"issue":"1","key":"1549_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jval.2016.11.006","volume":"20","author":"AJ Wailoo","year":"2017","unstructured":"Wailoo AJ, Hernandez-Alava M, Manca A, Mejia A, Ray J, Crawford B, et al. Mapping to estimate health-state utility from non-preference-based outcome measures: an ISPOR good practices for outcomes research task force report. Value Health. 2017;20(1):18\u201327. https:\/\/doi.org\/10.1016\/j.jval.2016.11.006.","journal-title":"Value Health."},{"issue":"9630","key":"1549_CR16","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/s0140-6736(08)60921-6","volume":"21","author":"MR Lunn","year":"2008","unstructured":"Lunn MR, Wang CH. Spinal muscular atrophy. Lancet. 2008;21(9630):2120\u201333. https:\/\/doi.org\/10.1016\/s0140-6736(08)60921-6.","journal-title":"Lancet"},{"issue":"1","key":"1549_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy: a literature review. Orphanet J Rare Dis. 2017;12(1):124. https:\/\/doi.org\/10.1186\/s13023-017-0671-8.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"1549_CR18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jacbts.2016.06.003","volume":"1","author":"GA Van Norman","year":"2016","unstructured":"Van Norman GA. Drugs and devices: comparison of European and US approval processes. JACC Basic Transl Sci. 2016;1(5):399\u2013412. https:\/\/doi.org\/10.1016\/j.jacbts.2016.06.003.","journal-title":"JACC Basic Transl Sci"},{"issue":"15","key":"1549_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241511939","volume":"24","author":"H Nishio","year":"2023","unstructured":"Nishio H, Niba ETE, Saito T, Okamoto K, Takeshima Y, Awano H. Spinal muscular atrophy: the past, present, and future of diagnosis and treatment. Int J Mol Sci. 2023;24(15):11939. https:\/\/doi.org\/10.3390\/ijms241511939.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"1549_CR20","doi-asserted-by":"publisher","first-page":"4922","DOI":"10.1007\/s00415-023-11811-1","volume":"270","author":"F Heinrich","year":"2023","unstructured":"Heinrich F, Cordts I, G\u00fcnther R, Stolte B, Zeller D, Schr\u00f6ter C, et al. Economic evaluation of motor neuron diseases: a nationwide cross-sectional analysis in Germany. J Neurol. 2023;270(10):4922\u201338. https:\/\/doi.org\/10.1007\/s00415-023-11811-1.","journal-title":"J Neurol"},{"issue":"4","key":"1549_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare13040428","volume":"13","author":"M Zhao","year":"2025","unstructured":"Zhao M, Ding S, Zhao Y, Lin C, Han Y. Healthcare resource utilization, economic burden, and multi-level medical security system for individuals with spinal muscular atrophy in Shaanxi province, China. Healthcare. 2025;13(4):428. https:\/\/doi.org\/10.3390\/healthcare13040428.","journal-title":"Healthcare"},{"issue":"1","key":"1549_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-023-02204-z","volume":"21","author":"RH Xu","year":"2023","unstructured":"Xu RH, Ma B, Xin H, Zhang H, Zeng Y, Luo N, et al. Measurement properties of the EQ-5D-5L and PROPr in patients with spinal muscular atrophy. Health Qual Life Outcomes. 2023;21(1):123. https:\/\/doi.org\/10.1186\/s12955-023-02204-z.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"1549_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13010110","volume":"13","author":"C Wohnrade","year":"2023","unstructured":"Wohnrade C, Velling AK, Mix L, Wurster CD, Cordts I, Stolte B, et al. Health-related quality of life in spinal muscular atrophy patients and their caregivers: a prospective, cross-sectional, multi-center analysis. Brain Sci. 2023;13(1):110. https:\/\/doi.org\/10.3390\/brainsci13010110.","journal-title":"Brain Sci"},{"issue":"7","key":"1549_CR24","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1007\/s11136-024-03665-5","volume":"33","author":"E Landfeldt","year":"2024","unstructured":"Landfeldt E, Leibrock B, Hussong J, Thiele S, Walter MC, Moehler E, et al. Health-related quality of life of adults with spinal muscular atrophy: insights from a nationwide patient registry in Germany. Qual Life Res. 2024;33(7):1949\u201359. https:\/\/doi.org\/10.1007\/s11136-024-03665-5.","journal-title":"Qual Life Res"},{"issue":"12","key":"1549_CR25","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1182\/blood-2005-04-1717","volume":"106","author":"C Parker","year":"2005","unstructured":"Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106(12):3699\u2013709. https:\/\/doi.org\/10.1182\/blood-2005-04-1717.","journal-title":"Blood"},{"issue":"1","key":"1549_CR26","doi-asserted-by":"publisher","first-page":"17028","DOI":"10.1038\/nrdp.2017.28","volume":"3","author":"A Hill","year":"2017","unstructured":"Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017;3(1):17028. https:\/\/doi.org\/10.1038\/nrdp.2017.28.","journal-title":"Nat Rev Dis Primers"},{"issue":"17","key":"1549_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25179477","volume":"25","author":"P Hillmen","year":"2024","unstructured":"Hillmen P, Horneff R, Yeh M, Kolev M, Deschatelets P. Navigating the complement pathway to optimize PNH treatment with pegcetacoplan and other currently approved complement inhibitors. Int J Mol Sci. 2024;25(17):9477. https:\/\/doi.org\/10.3390\/ijms25179477.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1549_CR28","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.3390\/jcm14092889","volume":"14","author":"R Bini","year":"2025","unstructured":"Bini R, D\u2019Anna L, Valsecchi D, Mazzoni S, Perrone V, Degli EL. Real-world evidence of the disease burden and economic impact of paroxysmal nocturnal hemoglobinuria in Italy. J Clin Med. 2025;14(9):2889. https:\/\/doi.org\/10.3390\/jcm14092889.","journal-title":"J Clin Med"},{"key":"1549_CR29","unstructured":"Patients HfP. White Paper on the living conditions of patients with Pproxysmal nocturnal hemoglobinuriaIn China. 2023. https:\/\/www.isun.org.cn\/uploadfile\/2025\/0410\/20250410024256330.pdf. Accessed 7 Oct 2025."},{"issue":"1","key":"1549_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-021-01771-3","volume":"19","author":"I Spronk","year":"2021","unstructured":"Spronk I, Polinder S, Bonsel GJ, Janssen MF, Haagsma JA. The relation between EQ-5D and fatigue in a Dutch general population sample: an explorative study. Health Qual Life Outcomes. 2021;19(1):135. https:\/\/doi.org\/10.1186\/s12955-021-01771-3.","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"1549_CR31","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2022-0178","volume":"12","author":"P Wojciechowski","year":"2023","unstructured":"Wojciechowski P, Wdowiak M, Hakimi Z, Wilson K, Fishman J, Nazir J, et al. Mapping the EORTC QLQ-C30 onto the EQ-5D-5L index for patients with paroxysmal nocturnal hemoglobinuria in France. J Comp Eff Res. 2023;12(5):e220178. https:\/\/doi.org\/10.57264\/cer-2022-0178.","journal-title":"J Comp Eff Res"},{"issue":"1","key":"1549_CR32","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jval.2012.10.010","volume":"16","author":"L Longworth","year":"2013","unstructured":"Longworth L, Rowen D. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value Health. 2013;16(1):202\u201310. https:\/\/doi.org\/10.1016\/j.jval.2012.10.010.","journal-title":"Value Health"},{"issue":"1","key":"1549_CR33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/0272989x05284108","volume":"26","author":"AM Gray","year":"2006","unstructured":"Gray AM, Rivero-Arias O, Clarke PM. Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Med Decis Mak. 2006;26(1):18\u201329. https:\/\/doi.org\/10.1177\/0272989x05284108.","journal-title":"Med Decis Mak"},{"issue":"6","key":"1549_CR34","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1007\/s12185-018-2409-3","volume":"107","author":"Y Ueda","year":"2018","unstructured":"Ueda Y, Obara N, Yonemura Y, Noji H, Masuko M, Seki Y, et al. Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan. Int J Hematol. 2018;107(6):656\u201365. https:\/\/doi.org\/10.1007\/s12185-018-2409-3.","journal-title":"Int J Hematol"},{"issue":"3 Suppl. 2","key":"1549_CR35","first-page":"13","volume":"34","author":"D Cella","year":"1997","unstructured":"Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997;34(3 Suppl. 2):13\u20139.","journal-title":"Semin Hematol"},{"issue":"2","key":"1549_CR36","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/cam4.1953","volume":"8","author":"CP Escalante","year":"2019","unstructured":"Escalante CP, Chisolm S, Song J, Richardson M, Salkeld E, Aoki E, et al. Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria. Cancer Med. 2019;8(2):543\u201353. https:\/\/doi.org\/10.1002\/cam4.1953.","journal-title":"Cancer Med"},{"issue":"10","key":"1549_CR37","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s40273-015-0312-9","volume":"33","author":"S Petrou","year":"2015","unstructured":"Petrou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Froud R, et al. The MAPS reporting statement for studies mapping onto generic preference-based outcome measures: explanation and elaboration. Pharmacoeconomics. 2015;33(10):993\u20131011. https:\/\/doi.org\/10.1007\/s40273-015-0312-9.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"1549_CR38","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40258-015-0191-4","volume":"13","author":"S Petrou","year":"2015","unstructured":"Petrou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Froud R, et al. Preferred reporting items for studies mapping onto preference-based outcome measures: the MAPS statement. Appl Health Econ Health Policy. 2015;13(5):437\u201343. https:\/\/doi.org\/10.1007\/s40258-015-0191-4.","journal-title":"Appl Health Econ Health Policy"},{"issue":"6","key":"1549_CR39","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40273-020-00893-8","volume":"38","author":"AJ Thompson","year":"2020","unstructured":"Thompson AJ, Turner AJ. A comparison of the EQ-5D-3L and EQ-5D-5L. Pharmacoeconomics. 2020;38(6):575\u201391. https:\/\/doi.org\/10.1007\/s40273-020-00893-8.","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"1549_CR40","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336. https:\/\/doi.org\/10.1007\/s11136-011-9903-x.","journal-title":"Qual Life Res"},{"issue":"8","key":"1549_CR41","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s10198-020-01195-8","volume":"21","author":"M Kennedy-Martin","year":"2020","unstructured":"Kennedy-Martin M, Slaap B, Herdman M, van Reenen M, Kennedy-Martin T, Greiner W, et al. Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. Eur J Health Econ. 2020;21(8):1245\u201357.","journal-title":"Eur J Health Econ"},{"issue":"4","key":"1549_CR42","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jval.2016.11.016","volume":"20","author":"N Luo","year":"2017","unstructured":"Luo N, Liu G, Li M, Guan H, Jin X, Rand-Hendriksen K. Estimating an EQ-5D-5L value set for China. Value Health. 2017;20(4):662\u20139. https:\/\/doi.org\/10.1016\/j.jval.2016.11.016.","journal-title":"Value Health"},{"issue":"1","key":"1549_CR43","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40258-024-00919-8","volume":"23","author":"C Mukuria","year":"2025","unstructured":"Mukuria C, Rowen D, Mulhern B, McDool E, Kharroubi S, Bjorner JB, et al. The short form 6 dimensions (SF-6D): development and evolution. Appl Health Econ Health Policy. 2025;23(1):19\u201333. https:\/\/doi.org\/10.1007\/s40258-024-00919-8.","journal-title":"Appl Health Econ Health Policy"},{"issue":"6","key":"1549_CR44","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/mlr.0000000000001325","volume":"58","author":"JE Brazier","year":"2020","unstructured":"Brazier JE, Mulhern BJ, Bjorner JB, Gandek B, Rowen D, Alonso J, et al. Developing a new version of the SF-6D health state classification system from the SF-36v2: SF-6Dv2. Med Care. 2020;58(6):557\u201365. https:\/\/doi.org\/10.1097\/mlr.0000000000001325.","journal-title":"Med Care"},{"issue":"5","key":"1549_CR45","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40273-020-00997-1","volume":"39","author":"J Wu","year":"2021","unstructured":"Wu J, Xie S, He X, Chen G, Bai G, Feng D, et al. Valuation of SF-6Dv2 health states in China using time trade-off and discrete-choice experiment with a duration dimension. Pharmacoeconomics. 2021;39(5):521\u201335. https:\/\/doi.org\/10.1007\/s40273-020-00997-1.","journal-title":"Pharmacoeconomics"},{"issue":"432","key":"1549_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.120059","volume":"15","author":"D Trundell","year":"2022","unstructured":"Trundell D, Skalicky A, Staunton H, Hareendran A, Le Scouiller S, Barrett L, et al. Development of the SMA independence scale-upper limb module (SMAIS-ULM): a novel scale for individuals with type 2 and non-ambulant type 3 SMA. J Neurol Sci. 2022;15(432):120059. https:\/\/doi.org\/10.1016\/j.jns.2021.120059.","journal-title":"J Neurol Sci"},{"issue":"1","key":"1549_CR47","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40120-022-00411-2","volume":"12","author":"JF V\u00e1zquez-Costa","year":"2023","unstructured":"V\u00e1zquez-Costa JF, Branas-Pampill\u00f3n M, Medina-Cantillo J, Povedano M, Pitarch-Castellano I, L\u00f3pez-Lobato M, et al. Validation of a set of instruments to assess patient- and caregiver-oriented measurements in spinal muscular atrophy: results of the SMA-TOOL study. Neurol Ther. 2023;12(1):89\u2013105. https:\/\/doi.org\/10.1007\/s40120-022-00411-2.","journal-title":"Neurol Ther"},{"issue":"1","key":"1549_CR48","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s41687-021-00376-0","volume":"5","author":"RP Daly","year":"2021","unstructured":"Daly RP, Jalbert JJ, Keith S, Symonds T, Shammo J. A novel patient-reported outcome instrument assessing the symptoms of paroxysmal nocturnal hemoglobinuria, the PNH-SQ. J Patient Rep Outcomes. 2021;5(1):102. https:\/\/doi.org\/10.1186\/s41687-021-00376-0.","journal-title":"J Patient Rep Outcomes."},{"issue":"1","key":"1549_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01532-3","volume":"15","author":"K Weisshaar","year":"2020","unstructured":"Weisshaar K, Ewald H, Halter J, Gerull S, Sch\u00f6nfeld S, Senft Y, et al. Development of a patient-reported outcome questionnaire for aplastic anemia and paroxysmal nocturnal hemoglobinuria (PRO-AA\/PNH). Orphanet J Rare Dis. 2020;15(1):249. https:\/\/doi.org\/10.1186\/s13023-020-01532-3.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"1549_CR50","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","volume":"13","author":"SB Yellen","year":"1997","unstructured":"Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13(2):63\u201374. https:\/\/doi.org\/10.1016\/S0885-3924(96)00274-6.","journal-title":"J Pain Symptom Manage"},{"key":"1549_CR51","unstructured":"Group F. FACT-An scoring guidelines (Version 4). 2003. https:\/\/www.facit.org\/measures-scoring-downloads\/fact-an-scoring-downloads. Accessed 21 May 2003."},{"issue":"3","key":"1549_CR52","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s11136-023-03568-x","volume":"33","author":"W Guo","year":"2024","unstructured":"Guo W, Xie S, Wang D, Wu J. Mapping IWQOL-lite onto EQ-5D-5L and SF-6Dv2 among overweight and obese population in China. Qual Life Res. 2024;33(3):817\u201329. https:\/\/doi.org\/10.1007\/s11136-023-03568-x.","journal-title":"Qual Life Res"},{"issue":"1","key":"1549_CR53","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1177\/0272989x07309642","volume":"28","author":"D Mortimer","year":"2008","unstructured":"Mortimer D, Segal L. Comparing the incomparable? A systematic review of competing techniques for converting descriptive measures of health status into QALY-weights. Med Decis Mak. 2008;28(1):66\u201389. https:\/\/doi.org\/10.1177\/0272989x07309642.","journal-title":"Med Decis Mak"},{"issue":"11","key":"1549_CR54","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1007\/s11136-018-1981-6","volume":"27","author":"AN Lamu","year":"2018","unstructured":"Lamu AN, Olsen JA. Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D. Qual Life Res. 2018;27(11):2823\u201339. https:\/\/doi.org\/10.1007\/s11136-018-1981-6.","journal-title":"Qual Life Res"},{"issue":"8","key":"1549_CR55","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.jval.2012.07.007","volume":"15","author":"A Hawton","year":"2012","unstructured":"Hawton A, Green C, Telford C, Zajicek J, Wright D. Using the multiple sclerosis impact scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D. Value Health. 2012;15(8):1084\u201391. https:\/\/doi.org\/10.1016\/j.jval.2012.07.007.","journal-title":"Value Health"},{"issue":"4","key":"1549_CR56","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/0272989x06290496","volume":"26","author":"PW Sullivan","year":"2006","unstructured":"Sullivan PW, Ghushchyan V. Mapping the EQ-5D index from the SF-12: US general population preferences in a nationally representative sample. Med Decis Mak. 2006;26(4):401\u20139. https:\/\/doi.org\/10.1177\/0272989x06290496.","journal-title":"Med Decis Mak"},{"issue":"Suppl. 1","key":"1549_CR57","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40273-017-0548-7","volume":"35","author":"R Ara","year":"2017","unstructured":"Ara R, Rowen D, Mukuria C. The use of mapping to estimate health state utility values. Pharmacoeconomics. 2017;35(Suppl. 1):57\u201366. https:\/\/doi.org\/10.1007\/s40273-017-0548-7.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1549_CR58","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11136-009-9558-z","volume":"19","author":"H Dakin","year":"2010","unstructured":"Dakin H, Petrou S, Haggard M, Benge S, Williamson I. Mapping analyses to estimate health utilities based on responses to the OM8-30 Otitis Media Questionnaire. Qual Life Res. 2010;19(1):65\u201380. https:\/\/doi.org\/10.1007\/s11136-009-9558-z.","journal-title":"Qual Life Res"},{"issue":"4","key":"1549_CR59","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s40261-016-0377-z","volume":"36","author":"MA Ruiz","year":"2016","unstructured":"Ruiz MA, Guti\u00e9rrez LL, Monroy M, Rejas J. Mapping of the OAB-SF Questionnaire onto EQ-5D in Spanish patients with overactive bladder. Clin Drug Invest. 2016;36(4):267\u201379. https:\/\/doi.org\/10.1007\/s40261-016-0377-z.","journal-title":"Clin Drug Invest"},{"issue":"6","key":"1549_CR60","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jval.2017.09.017","volume":"21","author":"LA Gray","year":"2018","unstructured":"Gray LA, Hern\u00e1ndez Alava M, Wailoo AJ. Development of methods for the mapping of utilities using mixture models: mapping the AQLQ-S to the EQ-5D-5L and the HUI3 in patients with asthma. Value Health. 2018;21(6):748\u201357. https:\/\/doi.org\/10.1016\/j.jval.2017.09.017.","journal-title":"Value Health."},{"issue":"12","key":"1549_CR61","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.jval.2018.06.006","volume":"21","author":"LA Gray","year":"2018","unstructured":"Gray LA, Wailoo AJ, Hernandez AM. Mapping the FACT-B Instrument to EQ-5D-3L in patients with breast cancer using adjusted limited dependent variable mixture models versus response mapping. Value Health. 2018;21(12):1399\u2013405. https:\/\/doi.org\/10.1016\/j.jval.2018.06.006.","journal-title":"Value Health."},{"issue":"1","key":"1549_CR62","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/1536867X1801800105","volume":"18","author":"LA Gray","year":"2018","unstructured":"Gray LA, Hernandez AM. A command for fitting mixture regression models for bounded dependent variables using the beta distribution. Stata J. 2018;18(1):51\u201375.","journal-title":"Stata J"},{"issue":"3","key":"1549_CR63","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jval.2011.12.014","volume":"15","author":"M Hern\u00e1ndez Alava","year":"2012","unstructured":"Hern\u00e1ndez Alava M, Wailoo AJ, Ara R. Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. Value Health. 2012;15(3):550\u201361. https:\/\/doi.org\/10.1016\/j.jval.2011.12.014.","journal-title":"Value Health."},{"key":"1549_CR64","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1177\/1536867X1501500307","volume":"15","author":"MH Alava","year":"2015","unstructured":"Alava MH, Wailoo AJ. Fitting adjusted limited dependent variable mixture models to EQ-5D. Stata J. 2015;15:737\u201350.","journal-title":"Stata J"},{"issue":"5","key":"1549_CR65","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/MLR.0b013e318207e9a8","volume":"49","author":"QA Le","year":"2011","unstructured":"Le QA, Doctor JN. Probabilistic mapping of descriptive health status responses onto health state utilities using Bayesian networks: an empirical analysis converting SF-12 into EQ-5D utility index in a national US sample. Med Care. 2011;49(5):451\u201360. https:\/\/doi.org\/10.1097\/MLR.0b013e318207e9a8.","journal-title":"Med Care"},{"issue":"9","key":"1549_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta18090","volume":"18","author":"L Longworth","year":"2014","unstructured":"Longworth L, Yang Y, Young T, Mulhern B, Hern\u00e1ndez Alava M, Mukuria C, et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Health Technol Assess. 2014;18(9):1\u2013224. https:\/\/doi.org\/10.3310\/hta18090.","journal-title":"Health Technol Assess"},{"issue":"5","key":"1549_CR67","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s10198-021-01287-z","volume":"22","author":"AA Shafie","year":"2021","unstructured":"Shafie AA, Chhabra IK, Wong JHY, Mohammed NS. Mapping PedsQL\u2122 Generic Core Scales to EQ-5D-3L utility scores in transfusion-dependent thalassemia patients. Eur J Health Econ. 2021;22(5):735\u201347. https:\/\/doi.org\/10.1007\/s10198-021-01287-z.","journal-title":"Eur J Health Econ"},{"issue":"7","key":"1549_CR68","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s11136-009-9499-6","volume":"18","author":"N Payakachat","year":"2009","unstructured":"Payakachat N, Summers KH, Pleil AM, Murawski MM, Thomas J 3rd, et al. Predicting EQ-5D utility scores from the 25-item National Eye Institute Vision Function Questionnaire (NEI-VFQ 25) in patients with age-related macular degeneration. Qual Life Res. 2009;18(7):801\u201313. https:\/\/doi.org\/10.1007\/s11136-009-9499-6.","journal-title":"Qual Life Res"},{"issue":"8","key":"1549_CR69","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s10198-019-01088-5","volume":"20","author":"F Yang","year":"2019","unstructured":"Yang F, Wong CKH, Luo N, Piercy J, Moon R, Jackson J. Mapping the kidney disease quality of life 36-item short form survey (KDQOL-36) to the EQ-5D-3L and the EQ-5D-5L in patients undergoing dialysis. Eur J Health Econ. 2019;20(8):1195\u2013206. https:\/\/doi.org\/10.1007\/s10198-019-01088-5.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"1549_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-014-0180-6","volume":"12","author":"YB Cheung","year":"2014","unstructured":"Cheung YB, Luo N, Ng R, Lee CF. Mapping the functional assessment of cancer therapy-breast (FACT-B) to the 5-level EuroQoL Group\u2019s 5-dimension questionnaire (EQ-5D-5L) utility index in a multi-ethnic Asian population. Health Qual Life Outcomes. 2014;12(1):180. https:\/\/doi.org\/10.1186\/s12955-014-0180-6.","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"1549_CR71","first-page":"730","volume":"40","author":"KM Ho","year":"2012","unstructured":"Ho KM. Scatter plot and correlation coefficient. Anaesth Intensive Care. 2012;40(4):730\u20131.","journal-title":"Anaesth Intensive Care"},{"issue":"2","key":"1549_CR72","doi-asserted-by":"publisher","first-page":"141","DOI":"10.11613\/bm.2015.015","volume":"25","author":"D Giavarina","year":"2015","unstructured":"Giavarina D. Understanding bland altman analysis. Biochem Med. 2015;25(2):141\u201351. https:\/\/doi.org\/10.11613\/bm.2015.015.","journal-title":"Biochem Med"},{"key":"1549_CR73","unstructured":"StataCorp. Stata Statistical Software: Release 15. 2017."},{"key":"1549_CR74","volume-title":"R: a language and environment for statistical computing","author":"Team RC","year":"2024","unstructured":"Team RC. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2024."},{"issue":"1","key":"1549_CR75","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12955-024-02276-5","volume":"22","author":"L Yu","year":"2024","unstructured":"Yu L, Yang H, Lu L, Fang Y, Zhang X, Li S, et al. Developing mapping algorithms to predict EQ-5D health utility values from Bath Ankylosing Spondylitis Disease Activity Index and Bath Ankylosing Spondylitis Functional Index among patients with Ankylosing Spondylitis. Health Qual Life Outcomes. 2024;22(1):61. https:\/\/doi.org\/10.1186\/s12955-024-02276-5.","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"1549_CR76","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s11136-013-0517-3","volume":"23","author":"QA Le","year":"2014","unstructured":"Le QA. Probabilistic mapping of the health status measure SF-12 onto the health utility measure EQ-5D using the US-population-based scoring models. Qual Life Res. 2014;23(2):459\u201366. https:\/\/doi.org\/10.1007\/s11136-013-0517-3.","journal-title":"Qual Life Res"},{"issue":"7","key":"1549_CR77","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1177\/0272989x15584921","volume":"35","author":"S Kent","year":"2015","unstructured":"Kent S, Gray A, Schlackow I, Jenkinson C, McIntosh E. Mapping from the Parkinson\u2019s Disease Questionnaire PDQ-39 to the generic EuroQol EQ-5D-3L: the value of mixture models. Med Decis Mak. 2015;35(7):902\u201311. https:\/\/doi.org\/10.1177\/0272989x15584921.","journal-title":"Med Decis Mak"},{"issue":"3","key":"1549_CR78","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1007\/s00415-020-10227-5","volume":"268","author":"C Binz","year":"2021","unstructured":"Binz C, Schreiber-Katz O, Kumpe M, Ranxha G, Siegler H, Wieselmann G, et al. An observational cohort study on impact, dimensions and outcome of perceived fatigue in adult 5q-spinal muscular atrophy patients receiving nusinersen treatment. J Neurol. 2021;268(3):950\u201362. https:\/\/doi.org\/10.1007\/s00415-020-10227-5.","journal-title":"J Neurol"},{"issue":"5","key":"1549_CR79","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3233\/jnd-230011","volume":"10","author":"J Sun","year":"2023","unstructured":"Sun J, Harrington MA, Porter B. Sex difference in spinal muscular atrophy patients: are males more vulnerable? J Neuromuscul Dis. 2023;10(5):847\u201367. https:\/\/doi.org\/10.3233\/jnd-230011.","journal-title":"J Neuromuscul Dis"},{"issue":"12","key":"1549_CR80","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/jnnp-2022-329320","volume":"93","author":"L Maggi","year":"2022","unstructured":"Maggi L, Bello L, Bonanno S, Govoni A, Caponnetto C, Passamano L, et al. Adults with spinal muscular atrophy: a large-scale natural history study shows gender effect on disease. J Neurol Neurosurg Psychiatry. 2022;93(12):1253\u201361. https:\/\/doi.org\/10.1136\/jnnp-2022-329320.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"1549_CR81","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1016\/s2468-2667(24)00053-7","volume":"9","author":"V Patwardhan","year":"2024","unstructured":"Patwardhan V, Gil GF, Arrieta A, Cagney J, DeGraw E, Herbert ME, et al. Differences across the lifespan between females and males in the top 20 causes of disease burden globally: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Public health. 2024;9(5):e282\u201394. https:\/\/doi.org\/10.1016\/s2468-2667(24)00053-7.","journal-title":"Lancet Public health."},{"issue":"1","key":"1549_CR82","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1186\/s12913-025-13020-0","volume":"25","author":"DS Rata Mohan","year":"2025","unstructured":"Rata Mohan DS, Jawahir S, Manual A, Abdul Mutalib NE, Mohd Noh SN, Ab Rahim I, et al. Gender differences in health-seeking behaviour: insights from the National Health and Morbidity Survey 2019. BMC Health Serv Res. 2025;25(1):900. https:\/\/doi.org\/10.1186\/s12913-025-13020-0.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"1549_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-025-23241-x","volume":"25","author":"H Hua","year":"2025","unstructured":"Hua H, Yang K, Wei Z, Hu W, Jin S, Wang J. Depression and anxiety symptoms and associated factors among community residents in Shenzhen, China: a cross-sectional study. BMC Public Health. 2025;25(1):2148. https:\/\/doi.org\/10.1186\/s12889-025-23241-x.","journal-title":"BMC Public Health"},{"issue":"1","key":"1549_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-020-01611-w","volume":"18","author":"Y Hagiwara","year":"2020","unstructured":"Hagiwara Y, Shiroiwa T, Taira N, Kawahara T, Konomura K, Noto S, et al. Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer. Health Qual Life Outcomes. 2020;18(1):354. https:\/\/doi.org\/10.1186\/s12955-020-01611-w.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"1549_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-020-01368-2","volume":"18","author":"S Kularatna","year":"2020","unstructured":"Kularatna S, Senanayake S, Chen G, Parsonage W. Mapping the Minnesota living with heart failure questionnaire (MLHFQ) to EQ-5D-5L in patients with heart failure. Health Qual Life Outcomes. 2020;18(1):115. https:\/\/doi.org\/10.1186\/s12955-020-01368-2.","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"1549_CR86","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s11136-023-03540-9","volume":"33","author":"D Huang","year":"2024","unstructured":"Huang D, Zeng D, Tang Y, Jiang L, Yang Q. Mapping the EORTC QLQ-C30 and QLQ H&N35 to the EQ-5D-5L and SF-6D for papillary thyroid carcinoma. Qual Life Res. 2024;33(2):491\u2013505. https:\/\/doi.org\/10.1007\/s11136-023-03540-9.","journal-title":"Qual Life Res"},{"issue":"1","key":"1549_CR87","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11136-008-9420-8","volume":"18","author":"N Kontodimopoulos","year":"2009","unstructured":"Kontodimopoulos N, Pappa E, Papadopoulos AA, Tountas Y, Niakas D. Comparing SF-6D and EQ-5D utilities across groups differing in health status. Qual Life Res. 2009;18(1):87\u201397. https:\/\/doi.org\/10.1007\/s11136-008-9420-8.","journal-title":"Qual Life Res"},{"issue":"14","key":"1549_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11144097","volume":"11","author":"N Kontodimopoulos","year":"2022","unstructured":"Kontodimopoulos N, Stamatopoulou E, Gazi S, Moschou D, Krikelis M, Talias MA. A comparison of EQ-5D-3L, EQ-5D-5L, and SF-6D utilities of patients with musculoskeletal disorders of different severity: a health-related quality of life approach. J Clin Med. 2022;11(14):4097.","journal-title":"J Clin Med"},{"issue":"1","key":"1549_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03178-x","volume":"19","author":"H Yu","year":"2024","unstructured":"Yu H, Duan S, Wang P, Fu R, Lv Z, Yu Y, et al. Health-related quality of life and influencing factors of patients with paroxysmal nocturnal hemoglobinuria in China. Orphanet J Rare Dis. 2024;19(1):186. https:\/\/doi.org\/10.1186\/s13023-024-03178-x.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"1549_CR90","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1007\/s11136-023-03351-y","volume":"32","author":"A Ayala","year":"2023","unstructured":"Ayala A, Ramallo-Fari\u00f1a Y, Bilbao-Gonzalez A, Forjaz MJ. Mapping the EQ-5D-5L from the Spanish national health survey functional disability scale through Bayesian networks. Qual Life Res. 2023;32(6):1785\u201394. https:\/\/doi.org\/10.1007\/s11136-023-03351-y.","journal-title":"Qual Life Res"},{"issue":"1","key":"1549_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-023-02151-9","volume":"21","author":"C Li","year":"2023","unstructured":"Li C, Dou L, Fu Q, Li S. Mapping the Seattle Angina Questionnaire to EQ-5D-5L in patients with coronary heart disease. Health Qual Life Outcomes. 2023;21(1):64. https:\/\/doi.org\/10.1186\/s12955-023-02151-9.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"1549_CR92","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1186\/s12885-021-08964-5","volume":"21","author":"LA Gray","year":"2021","unstructured":"Gray LA, Hernandez Alava M, Wailoo AJ. Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer. BMC Cancer. 2021;21(1):1237. https:\/\/doi.org\/10.1186\/s12885-021-08964-5.","journal-title":"BMC Cancer"},{"issue":"1","key":"1549_CR93","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/14737167.2018.1517046","volume":"19","author":"H Ameri","year":"2019","unstructured":"Ameri H, Yousefi M, Yaseri M, Nahvijou A, Arab M, Akbari Sari A. Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients. Expert Rev Pharmacoecon Outcomes Res. 2019;19(1):89\u201396. https:\/\/doi.org\/10.1080\/14737167.2018.1517046.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"1549_CR94","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1477-7525-6-51","volume":"6","author":"GR Barton","year":"2008","unstructured":"Barton GR, Sach TH, Jenkinson C, Avery AJ, Doherty M, Muir KR. Do estimates of cost-utility based on the EQ-5D differ from those based on the mapping of utility scores? Health Qual Life Outcomes. 2008;6(1):51. https:\/\/doi.org\/10.1186\/1477-7525-6-51.","journal-title":"Health Qual Life Outcomes"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01549-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01549-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01549-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T14:35:14Z","timestamp":1769783714000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01549-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":94,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1549"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01549-1","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"29 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ziwen Zhao, Zhao Shi, Lei Dou, Chaofan Li, and Shunping Li have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"This study involves human participants and this study was screened and approved by the Ethics Committee of the Centre for Health Management and Policy Research of Shandong University (No. ECSHCMSDU20230403 for SMA; No. ECCHMPSDU20210101 for PNH). All participants gave their informed consent by signing the consent form. All participants were free to quit at any time and at any stage of this research. Sensitive personal information such as patient identification numbers and names was strictly protected.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data are available upon reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The codes are available upon request to the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"CFL and SPL are the co-guarantors of the article\u2019s content. CFL and SPL contributed significantly to the conceptualization and design of the study. CFL, SPL, and ZS also participated in the revision of the manuscript. LD and ZWZ were responsible for the questionnaire survey and data acquisition. ZWZ and CFL conducted the data analysis and contributed to drafting the manuscript. All authors approved the final version of the manuscript and are accountable for the accuracy of the published content.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}